<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778527</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol #953</org_study_id>
    <nct_id>NCT04778527</nct_id>
  </id_info>
  <brief_title>A Crossover Adherence and Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention</brief_title>
  <official_title>A Randomized, Crossover Study to Compare Adherence, Preference and Acceptability of an Over-encapsulated Dual Prevention Pill (DPP Capsule) Containing Oral Pre-exposure Prophylaxis (PrEP) and a Combined Oral Contraceptive (COC) Versus Two Separate Tablets (PrEP and COC) Among Women at Risk of HIV and Unintended Pregnancy in Johannesburg, South Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, crossover study to compare adherence, preference and acceptability of an&#xD;
      over-encapsulated dual prevention pill (DPP capsule) containing oral pre-exposure prophylaxis&#xD;
      (PrEP) and a combined oral contraceptive (COC) versus two separate tablets (PrEP and COC)&#xD;
      among women at risk of HIV and unintended pregnancy in Johannesburg, South Africa&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare adherence to the DPP capsule</measure>
    <time_frame>At the end of Cycle 3 (each cycle is 28 days)</time_frame>
    <description>To compare adherence to the DPP capsule (Regimen A) versus 2 separate tablets (Regimen B) among women using each regimen daily for three 28-day menstrual cycles during the CROSSOVER period in women aged 16-40 in Johannesburg, SA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare adherence among women who choose the DPP capsule versus 2 separate capsules</measure>
    <time_frame>At the end of Cycle 3 (each cycle is 28 days)</time_frame>
    <description>To compare adherence among women who choose the DPP capsule (Regimen A) versus adherence among women who choose 2 separate tablets (Regimen B), each taken daily during the CHOICE period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Over-encapsulated DPP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single, over-encapsulated DPP taken once daily for three 28-day cycles (Regimen A) followed by two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles (Regimen B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two Separate Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles followed by a single, over-encapsulated DPP taken once daily for three 28-day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP tablet and a COC as one tablet</intervention_name>
    <description>a single over-encapsulated DPP containing a PrEP tablet and a COC</description>
    <arm_group_label>Over-encapsulated DPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrEP tablet and a COC as two separate tablets</intervention_name>
    <description>PrEP tablet and a COC as two separate tablets</description>
    <arm_group_label>Two Separate Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 16 through 40 years old (inclusive) at Screening, verified per site-specific SOPs.&#xD;
&#xD;
          -  Able and willing to provide informed consent per site SOPs. (If under the legal age of&#xD;
             consent [18 years old] be able to provide informed assent and obtain parental or&#xD;
             guardian consent, to be screened for and to enroll in the study.)&#xD;
&#xD;
          -  Fluent in spoken Zulu and/or English.&#xD;
&#xD;
          -  Able and willing to provide adequate locator information, as defined in site SOPs.&#xD;
&#xD;
          -  Able and willing to comply with all study procedures.&#xD;
&#xD;
          -  Post-menarche, per participant report at Screening.&#xD;
&#xD;
          -  Sexually active, defined as having had penile-vaginal sex with a male within the 3&#xD;
             months before Screening (per self-report).&#xD;
&#xD;
          -  At moderate to high risk of HIV infection based on validated risk measure, such as the&#xD;
             modified VOICE risk score.&#xD;
&#xD;
          -  Considers herself to be at moderate to high risk of HIV acquisition based on&#xD;
             self-assessment.&#xD;
&#xD;
          -  Has been using COCs for contraception for at least 3 months prior to Screening as&#xD;
             confirmed by contraceptive card and intends to continue using COCs for at least 12&#xD;
             months.&#xD;
&#xD;
          -  HIV-negative per rapid test at Screening and Enrollment per site-specific SOP (see&#xD;
             Appendix 3 for HIV testing algorithm).&#xD;
&#xD;
          -  Negative pregnancy test at Screening and Enrollment.&#xD;
&#xD;
          -  Negative for chlamydia, gonorrhea, trichomoniasis, and syphilis at Screening; women&#xD;
             who test positive at Screening may be treated and enrolled.&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAG) negative per blood test at Screening.&#xD;
&#xD;
          -  Normal estimated creatinine clearance (eCrCl) â‰¥ 60 ml/min per blood test at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive HIV test at Screening or Enrollment (see Appendix 3 for algorithm).&#xD;
&#xD;
          -  Positive pregnancy test at Screening or Enrollment.&#xD;
&#xD;
          -  Intends to become pregnant within the next 12 months.&#xD;
&#xD;
          -  Intolerance, SAE or laboratory abnormality associated with PrEP use in the past.&#xD;
&#xD;
          -  Use of PEP within 3 months of Screening (per self-report).&#xD;
&#xD;
          -  Breast feeding &lt; 6 months postpartum (per self-report).&#xD;
&#xD;
          -  Less than 6 weeks (&lt;=42 days) postpartum and not breastfeeding (per self-report).&#xD;
&#xD;
          -  For women 35 and older, currently smokes (self-report).&#xD;
&#xD;
          -  History of deep vein thrombosis / pulmonary embolism (self-report).&#xD;
&#xD;
          -  Prolonged immobilization (self-report).&#xD;
&#xD;
          -  Known thrombogenic mutation/complicated valvular disease (per self-report).&#xD;
&#xD;
          -  Ischemic heart disease (per self-report).&#xD;
&#xD;
          -  Systemic lupus erythematosus with positive or unknown antiphospholipid antibodies (per&#xD;
             self-report).&#xD;
&#xD;
          -  Migraines with aura (per self-report).&#xD;
&#xD;
          -  For women over 35 years old, migraines without aura (per self-report).&#xD;
&#xD;
          -  Current breast cancer or within 5 years of past breast cancer (per self-report).&#xD;
&#xD;
          -  Diabetes with nephropathy, retinopathy or neuropathy (per self-report).&#xD;
&#xD;
          -  Diabetes for &gt; 20 years (per self-report).&#xD;
&#xD;
          -  Symptomatic gall bladder disease (per self-report).&#xD;
&#xD;
          -  Severe Cirrhosis (per self-report).&#xD;
&#xD;
          -  Liver tumor (per self-report).&#xD;
&#xD;
          -  Estimated creatinine clearance (eCrCl) &lt; 60 ml/min per Screening blood test.&#xD;
&#xD;
          -  Any other condition the clinician feels would jeopardize the health and wellbeing of&#xD;
             the participant.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara Friedland, MPH</last_name>
    <phone>212-327-7045</phone>
    <email>bfriedland@popcouncil.org</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

